<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02051296</url>
  </required_header>
  <id_info>
    <org_study_id>RX000487</org_study_id>
    <nct_id>NCT02051296</nct_id>
  </id_info>
  <brief_title>Minocycline to Reduce Pain After Carpal Tunnel Release</brief_title>
  <official_title>A Trial of Minocycline for Pain After Carpal Tunnel and Trigger Release</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Palo Alto Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Palo Alto Health Care System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are looking at whether peri-operative minocycline will reduce the duration
      of pain after minor hand surgery: carpal tunnel release and trigger finger release.

      The investigators' hypothesis is that minocycline will reduce post-operative pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blinded randomized controlled trial. Patients are given 100mg of minocycline
      2 hours prior to their procedure and then 100mg two times a day for 5 days. The subjects are
      then contacted daily to check their level of pain. The investigators' outcome of interest is
      time to pain resolution.

      The investigators will perform a futility analysis to assess if a larger trial would be a
      reasonable next step after this pilot study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Pain Resolution</measure>
    <time_frame>up to 365 days</time_frame>
    <description>the time until patient answers no pain at surgical site for three consecutive days</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Post-operative Pain</condition>
  <arm_group>
    <arm_group_label>minocycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>perioperative minocycline for 5 days, starting 2 hours prior to surgery then 100mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLacebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>RCT blinded placebo trial</description>
    <arm_group_label>minocycline</arm_group_label>
    <other_name>Minocycline Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>RCT blinded placebo trial</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult, Veteran,

        Exclusion Criteria:

          -  Kidney failure, Liver failure, thrombocytopenia, ALS, SLE, Frailty, unable to
             understand survery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Curtin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Palo Alto Veterans Hsopital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palo Alto VA</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>January 26, 2014</study_first_submitted>
  <study_first_submitted_qc>January 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2014</study_first_posted>
  <results_first_submitted>November 23, 2016</results_first_submitted>
  <results_first_submitted_qc>May 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2018</results_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VA Palo Alto Health Care System</investigator_affiliation>
    <investigator_full_name>Catherine Curtin</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Minocycline</title>
          <description>perioperative minocycline for 5 days, starting 2 hours prior to surgery then 100mg BID for 5 days
Minocycline: RCT blinded placebo trial</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: two pills 2 hours prior to surgery then 1 pill BID
placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Allocated Intervention</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>withdraw prior to treatment</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Minocycline</title>
          <description>perioperative minocycline for 5 days, starting 2 hours prior to surgery then 100mg BID
Minocycline: RCT blinded placebo trial</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>PLacebo
placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="27" upper_limit="76"/>
                    <measurement group_id="B2" value="60" lower_limit="26" upper_limit="79"/>
                    <measurement group_id="B3" value="60" lower_limit="26" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Brief Pain Inventory(Short Form)</title>
          <description>The Brief Pain Inventory measures two constructs.
Each item is rated from 0, no pain/no interference, to 10, pain as bad as you can imagine/worst interference.
Pain severity score:calculated from the 4 items about pain intensity. It is scored as the mean/median of the seven interference items when all 4 items are not missing.
Pain interference score: It is scored as the mean/median of the seven interference items. This median can be used if more than 50%, or four of seven, of the total items have been completed on a given administration.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Brief Pain Inventory Severity Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="B2" value="5" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="B3" value="5" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brief Pain Inventory Interference Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="B2" value="4" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="B3" value="3" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>screen for Posttraumatic Stess Symptoms(SPTSS)</title>
          <description>The Brief SPTSS is a 17-item self-report measure that assesses DSM-IV symptoms of PTSD. For this survey, the respondents rated items on an 4-point scale ranging from 0 (&quot;not at all&quot;) to 4 (&quot;more than once everyday&quot;). The points were sum across all items for each participant.
A median score of 12 or higher has been used as the cut-off for psychological distress on this scale. [Dr. Eve Carlson personal communication] We dichotomized as low distress with a score less than 16 and high score 16 or greater. the range was from 0 to 68 points.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" lower_limit="0" upper_limit="58"/>
                    <measurement group_id="B2" value="9" lower_limit="0" upper_limit="68"/>
                    <measurement group_id="B3" value="9" lower_limit="0" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quick Disability Arm Shoulder and Hand(qDASH)</title>
          <description>The Quick Disability Arm Shoulder and Hand (QDASH) is a continuous variable to measure upper extremity physical function and disability. The QDASH consists of 11 items from the original 30-item DASH and has similar reliability and correlation with psychological stress as the full DASH. The scores range from 0 (best function) to 100 (worst function).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Quick Disability Arm Shoulder and Hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" lower_limit="5" upper_limit="91"/>
                    <measurement group_id="B2" value="45" lower_limit="5" upper_limit="91"/>
                    <measurement group_id="B3" value="41" lower_limit="5" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Shoulder and Hand Work</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" lower_limit="0" upper_limit="44"/>
                    <measurement group_id="B2" value="44" lower_limit="0" upper_limit="88"/>
                    <measurement group_id="B3" value="44" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Shoulder and Hand Play</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="B2" value="56" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="B3" value="50" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beck Depression Inventory-II(BDI-II)</title>
          <description>Beck Depression Inventory-II (BDI-II) is a widely used validated measure of depressive symptoms. It consists of 21 groups if statements. A score greater than 16 is the cutoff for depression.
scoring: The sum of the score for each of the 21 questions.
depression ranges:
Low 1-10 Normal ups and downs 11-16 Mild mood disturbance Moderate 17-20 Borderline clinical depression 21-30 Moderate depression Significant 31-40 Severe depression Over 40 Extreme depression</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9" lower_limit="0" upper_limit="39"/>
                    <measurement group_id="B2" value="8" lower_limit="0" upper_limit="38"/>
                    <measurement group_id="B3" value="8" lower_limit="0" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>RAND 36 Item Health Survey( short form(SF-36))</title>
          <description>All ques. are scored on a scale from 0(lowest)-100(highest) functioning (50 avg.)
Scoring: First, recoded per the scoring key. Scores represent the percentage of total possible score achieved. Second, avg. non missing items in same scale to create 8 scale scores .Scores represent the median for all items in the scale that the respondent answered.
Physical Functioning 10 Items Role Functioning/physical 4 Items Role Functioning/emotional 3 Items Energy/fatigue 4 Items Emotional well-being 5 Items Social functioning 2 Items Pain 2 Items General Health 5 Items Health Change 1 Item</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Physical Component Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="42" upper_limit="72"/>
                    <measurement group_id="B2" value="58" lower_limit="39" upper_limit="73"/>
                    <measurement group_id="B3" value="57" lower_limit="39" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="35" upper_limit="56"/>
                    <measurement group_id="B2" value="47" lower_limit="33" upper_limit="62"/>
                    <measurement group_id="B3" value="47" lower_limit="33" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Pain Resolution</title>
        <description>the time until patient answers no pain at surgical site for three consecutive days</description>
        <time_frame>up to 365 days</time_frame>
        <population>94 CTR enrolled and randomized, 83 completed and reached endpoint (43 in minocycline group and 40 in placebo group) 37 TFR enrolled and randomized, 31 completed and reached endpoint (15 in minocycline group and 16 in placebo group)</population>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>perioperative minocycline for 5 days, starting 2 hours prior to surgery then 100mg BID
Minocycline: RCT blinded placebo trial</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>PLacebo
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Pain Resolution</title>
          <description>the time until patient answers no pain at surgical site for three consecutive days</description>
          <population>94 CTR enrolled and randomized, 83 completed and reached endpoint (43 in minocycline group and 40 in placebo group) 37 TFR enrolled and randomized, 31 completed and reached endpoint (15 in minocycline group and 16 in placebo group)</population>
          <units>DAYS</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="3" upper_limit="365"/>
                    <measurement group_id="O2" value="15" lower_limit="3" upper_limit="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The patients were followed up for 6 months after surgery.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Minocycline</title>
          <description>perioperative minocycline for 5 days, starting 2 hours prior to surgery then 100mg BID
Minocycline: RCT blinded placebo trial</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>PLacebo
placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <description>&gt;7/10 by self report</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Catherine Curtin</name_or_title>
      <organization>VA HCS Palo Alto</organization>
      <phone>650-493-5000</phone>
      <email>ccurtin@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

